Researchers from Clínic-IDIBAPS, as part of the Clínic Barcelona Comprehensive Cancer Centre — a centre driven by Clínic, IDIBAPS and the Universit...
A study led by the Clínic-IDIBAPS reveals that the microbiota can predict and enhance patient response to one of the most innovative immunotherapie...
A team from Clínic-IDIBAPS has introduced a modification to a CAR-T immunotherapy for multiple myeloma that makes it more durable, according to res...
The Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved AR...
A study published recently in the journal Clinical Cancer Research identified biomarkers that can predict the response to CAR T-cell therapy target...
An international team, co-led by the Hospital Clínic-IDIBAPS, has identified four biomarkers that determine the risk of the recurrence of this canc...
The ”la Caixa” Foundation will allocate 4.6 million euros to promoting research at the Hospital Clínic Barcelona, in order to develop new, personal...
A multicentre study led by the Hospital Clínic Barcelona-IDIBAPS demonstrates the efficacy of the CAR T-cell therapy ARI0002h in treating patients...
The Hospital Clínic-IDIBAPS has developed the first CAR T-cell therapy in Europe to treat multiple myeloma, the second most common type of blood ca...
On Thursday, 11 November, the Spanish Cancer Association (AECC) awarded the AECC 2021 Grants for Cancer Research at an event held at the organizati...
